353 related articles for article (PubMed ID: 19690236)
1. The reduced anticoagulant effect of fondaparinux at low antithrombin levels.
Dempfle CE; Eichner J; Suvajac N; Ahmad-Nejad P; Neumaier M; Borggrefe M
Anesth Analg; 2009 Sep; 109(3):712-6. PubMed ID: 19690236
[TBL] [Abstract][Full Text] [Related]
2. Inter-individual variability of effect of 7 low molecular weight antithrombin-dependent anticoagulants studied in vitro with calibrated automated thrombography.
Hacquard M; Perrin J; Lelievre N; Vigneron C; Lecompte T
Thromb Res; 2011 Jan; 127(1):29-34. PubMed ID: 20850172
[TBL] [Abstract][Full Text] [Related]
3. Heptest-STAT, a new assay for monitoring of low-molecular-weight heparins, is not influenced by pregnancy-related changes of blood plasma.
Dempfle CE; Zharkowa U; Elmas E; Ahmad-Nejad P; Neumaier M; Borggrefe M
Thromb Haemost; 2009 Nov; 102(5):1001-6. PubMed ID: 19888540
[TBL] [Abstract][Full Text] [Related]
4. Determination of antithrombin-dependent factor Xa inhibitors by prothrombin-induced clotting time.
Harenberg J; Giese C; Hagedorn A; Traeger I; Fenyvesi T
Semin Thromb Hemost; 2007 Jul; 33(5):503-7. PubMed ID: 17629847
[TBL] [Abstract][Full Text] [Related]
5. Anticoagulant mechanisms of covalent antithrombin-heparin investigated by thrombelastography. Comparison with unfractionated heparin and low-molecular-weight heparin.
Atkinson HM; Mewhort-Buist TA; Berry LR; Chan AK
Thromb Haemost; 2009 Jul; 102(1):62-8. PubMed ID: 19572069
[TBL] [Abstract][Full Text] [Related]
6. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings.
Greinacher A; Alban S; Omer-Adam MA; Weitschies W; Warkentin TE
Thromb Res; 2008; 122(2):211-20. PubMed ID: 18262226
[TBL] [Abstract][Full Text] [Related]
7. Heparin chain-length dependence of factor Xa inhibition by antithrombin in plasma.
Rezaie AR
Thromb Res; 2007; 119(4):481-8. PubMed ID: 16515805
[TBL] [Abstract][Full Text] [Related]
8. Monitoring direct FXa-inhibitors and fondaparinux by Prothrombinase-induced Clotting Time (PiCT): relation to FXa-activity and influence of assay modifications.
Harder S; Parisius J; Picard-Willems B
Thromb Res; 2008; 123(2):396-403. PubMed ID: 18571698
[TBL] [Abstract][Full Text] [Related]
9. Development and clinical evaluation of two chromogenic substrate methods for monitoring fondaparinux sodium.
Klaeffling C; Piechottka G; Daemgen-von Brevern G; Mosch G; Mani H; Luxembourg B; Lindhoff-Last E
Ther Drug Monit; 2006 Jun; 28(3):375-81. PubMed ID: 16778722
[TBL] [Abstract][Full Text] [Related]
10. Low-dose fondaparinux in suspected heparin-induced thrombocytopenia in the critically ill.
Wester JP; Leyte A; Oudemans-van Straaten HM; Bosman RJ; van der Spoel JI; Haak EA; Porcelijn L; Zandstra DF
Neth J Med; 2007 Mar; 65(3):101-8. PubMed ID: 17387236
[TBL] [Abstract][Full Text] [Related]
11. Monitoring fondaparinux with the Sonoclot.
Nilsson CU; Engström M
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):619-22. PubMed ID: 17890948
[TBL] [Abstract][Full Text] [Related]
12. The significance of TFPI in clotting assays--comparison and combination with other anticoagulants.
Nordfang O; Kristensen HI; Valentin S; Ostergaard P; Wadt J
Thromb Haemost; 1993 Sep; 70(3):448-53. PubMed ID: 8259547
[TBL] [Abstract][Full Text] [Related]
13. Routine coagulation assays underestimate levels of antithrombin-dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis.
Potze W; Arshad F; Adelmeijer J; Blokzijl H; van den Berg AP; Porte RJ; Lisman T
Br J Haematol; 2013 Dec; 163(5):666-73. PubMed ID: 24219333
[TBL] [Abstract][Full Text] [Related]
14. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
[TBL] [Abstract][Full Text] [Related]
15. Functionality of fondaparinux (pentasaccharide) depends on clinical antithrombin levels.
Jeske WP; Walenga JM; Samama MM; Hoppensteadt D; Mayuga M; Fareed J
Blood Coagul Fibrinolysis; 2011 Apr; 22(3):206-10. PubMed ID: 21297455
[TBL] [Abstract][Full Text] [Related]
16. Effects of fondaparinux compared with dalteparin, enoxaparin and unfractionated heparin on human osteoblasts.
Matziolis G; Perka C; Disch A; Zippel H
Calcif Tissue Int; 2003 Oct; 73(4):370-9. PubMed ID: 12874702
[TBL] [Abstract][Full Text] [Related]
17. Inactivated antithrombins as fondaparinux antidotes: a promising alternative to haemostatic agents as assessed in vitro in a thrombin-generation assay.
Bourti Y; Fazavana J; Armand M; Saller F; Lasne D; Borgel D; Bianchini EP
Thromb Haemost; 2016 Aug; 116(3):452-60. PubMed ID: 27412396
[TBL] [Abstract][Full Text] [Related]
18. Conventional chromogenic heparin assays are influenced by patient's endogenous plasma Antithrombin levels.
Mitchell LG; Vegh P
Klin Padiatr; 2010 May; 222(3):164-7. PubMed ID: 20514621
[TBL] [Abstract][Full Text] [Related]
19. Laboratory-monitored fondaparinux and coagulation activity in association with total hip replacement.
Virtanen L; Salmela B; Leinonen J; Lemponen M; Huhtala J; Joutsi-Korhonen L; Lassila R
Blood Coagul Fibrinolysis; 2014 Sep; 25(6):597-603. PubMed ID: 24732174
[TBL] [Abstract][Full Text] [Related]
20. Anticoagulant effect of unfractionated heparin in antithrombin-depleted plasma in vitro.
Krulder JW; Strebus AF; Meinders AE; Briët E
Haemostasis; 1996; 26(2):85-9. PubMed ID: 9119287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
